Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
Description: Catalyst Pharmaceutical Partners, Inc. operates as development-stage specialty pharmaceutical company. The company focuses on the development and commercialization of novel prescription drugs targeting rare (orphan) neuromuscular and neurological diseases and disorders. Its principal product candidate is Firdapse, a proprietary form of amifampridine phosphate, which is in Phase III clinical trial for the treatment of Lambert-Eaton Myasthenic Syndrome. The company also develops CPP-115, a vigabatrin analog to treat infantile spasms and epilepsy, as well as other neurological conditions associated with reduced GABAergic signaling, such as post-traumatic stress disorder and Tourette syndrome. Catalyst Pharmaceutical Partners, Inc. has strategic collaboration agreement with BioMarin. The company was founded in 2002 and is based in Coral Gables, Florida.
|Shares Outstanding||EPS||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||Sales Growth - Q/Q||P/E|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-22.5%||ROE||-25.68%||ROI|
|Current Ratio||12.99||Quick Ratio||Long Term Debt/Equity||Debt Ratio||0.09|
|Gross Margin||Operating Margin||Net Profit Margin||Dividend Payout Ratio|
|Cash From Financing Activities||36.06 M||Cash From Investing Activities||-40 K||Cash From Operating Activities||-3.79 M||Gross Profit|
|Net Profit||-5.41 M||Operating Profit||-4.29 M||Total Assets||76.05 M||Total Current Assets||75.97 M|
|Total Current Liabilities||5.85 M||Total Debt||Total Liabilities||9.43 M||Total Revenue|
|High 52 week||6.11||Low 52 week||1.92||Last close||5.03||Last change||-0.98%|
|RSI||75.81||Average true range||0.28||Beta||0.62||Volume||310.27 K|
|Simple moving average 20 days||7.3%||Simple moving average 50 days||22.15%||Simple moving average 200 days||42.18%|
|Performance Week||-0.59%||Performance Month||23.59%||Performance Quart||60.19%||Performance Half||103.64%|
|Performance Year||71.67%||Performance Year-to-date||161.98%||Volatility daily||2.68%||Volatility weekly||6%|
|Volatility monthly||12.3%||Volatility yearly||42.6%||Relative Volume||298.06%||Average Volume||1.66 M|
|New High||New Low|
2020-05-11 19:25:11 | Catalyst Pharmaceutical CPRX Surpasses Q1 Earnings Estimates
2020-04-29 10:02:57 | Healthcare Pro Steven Boyd Is Gobbling Up These 3 Stocks
2020-04-29 05:33:00 | Is Catalyst Pharmaceuticals a Buy?
2020-04-15 11:30:03 | Catalyst CPRX Up 52.1% Since Last Earnings Report: Can It Continue?
2020-03-17 19:21:09 | Edited Transcript of CPRX earnings conference call or presentation 17-Mar-20 12:30pm GMT
2020-03-17 06:30:00 | Catalyst Pharmaceuticals, Inc. to Host Earnings Call
2020-03-09 12:30:04 | Catalyst Pharmaceutical CPRX Earnings Expected to Grow: What to Know Ahead of Q4 Release
2020-02-27 08:03:10 | Catalyst Pharmaceuticals Announces Support of Rare Disease Day 2020
2020-02-26 08:03:10 | Catalyst Pharmaceuticals to Present at the Cowen 40th Annual Health Care Conference
2020-02-24 09:42:15 | Based On Its ROE, Is Catalyst Pharmaceuticals, Inc. NASDAQ:CPRX A High Quality Stock?
2020-02-06 08:03:10 | Catalyst Pharmaceuticals to Present at the 22nd Annual BIO CEO & Investor Conference
2020-02-04 08:02:10 | Catalyst Pharmaceuticals Appoints David Ailinger as Vice President, Business Development
2020-01-15 08:58:01 | Implied Volatility Surging for Catalyst CPRX Stock Options
2020-01-07 09:17:02 | Catalyst Gives Preliminary Firdapse Estimates & Other Updates
2019-12-24 06:33:13 | Is Catalyst Pharmaceuticals, Inc. NASDAQ:CPRX Trading At A 44% Discount?
2019-12-13 14:45:19 | Is Catalyst Pharmaceuticals, Inc. CPRX A Good Stock To Buy?
2019-12-12 11:30:04 | Why Is Catalyst CPRX Down 5.3% Since Last Earnings Report?
2019-12-04 20:35:43 | Edited Transcript of CPRX earnings conference call or presentation 13-Nov-19 1:30pm GMT
2019-11-29 09:39:02 | Catalyst Focuses on Firdapse Label Expansion Amid Competition
2019-11-13 09:05:02 | Catalyst's CPRX Q3 Earnings Beat Estimates, Sales Miss
2019-11-12 18:26:11 | Catalyst Pharmaceutical CPRX Beats Q3 Earnings Estimates
2019-11-08 10:33:32 | 3 ‘Strong Buy’ Stocks to Buy on Weakness
2019-10-29 15:16:07 | Investors Can Find Strong Stocks with our First Profit Screen
2019-10-29 09:46:01 | Catalyst Pharma CPRX to Post Q3 Earnings: What's in Store?
2019-10-19 21:56:58 | Top Insider Buys Highlight for the Week of Oct. 18
2019-10-01 15:06:07 | Learn How to Find Top-Ranked 'Cheap' Stocks Under $10 with this Screener
2019-09-25 08:02:00 | Catalyst Pharmaceuticals to Participate in the 2019 Cantor Global Healthcare Conference
2019-09-19 10:37:31 | Should You Wait Before Investing In Catalyst Pharmaceuticals, Inc. NASDAQ:CPRX?
2019-09-18 09:31:01 | Buy These 7 Small Drugmakers to Boost Your Portfolio's Health
2019-09-13 10:00:02 | Catalyst Pharmaceutical CPRX is a Great Momentum Stock: Should You Buy?